xmab22841
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 29, 2019 (NCT03849469)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Cholangiocarcinoma · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Melanoma · Phase 1/Phase 2
- Nasopharyngeal Carcinoma · Phase 1
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Penile Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Rectal Neoplasms · Phase 1
- Small Cell Lung Carcinoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
- Vulvar Neoplasms · Phase 1
Mechanism of action
- Lymphocyte activation gene 3 proteinINHIBITOR
LAG3 inhibitor
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05695898 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2023 | University of California, San Francisco, Xencor |
| NCT03849469 | Phase 1 | May 29, 2019 | ICON, Xencor |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xencor | For profit | 2 | 1 | 2 | 2019 |
| ICON | For profit | 1 | 0 | 1 | 2019 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1